{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:26:52Z","timestamp":1759937212834},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ijrobp.2017.11.024","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T04:18:51Z","timestamp":1511324331000},"page":"695-701","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["First Report of NRG Oncology\/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy"],"prefix":"10.1016","volume":"100","author":[{"given":"Richard K.","family":"Valicenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard J.","family":"Trabulsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Girvigian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Shaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannie H.","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Schallenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.11.024_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0094-0143(05)70386-4","article-title":"Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control","volume":"24","author":"Pound","year":"1997","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","article-title":"Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan","volume":"61","author":"Soloway","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000475018","article-title":"Extent of disease based on initial bone scan: Important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2)","volume":"28","author":"J\u00f8rgensen","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","article-title":"Radioisotopes for the palliation of metastatic bone cancer: A systematic review","volume":"6","author":"Finlay","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib7","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/1097-0142(20000615)88:12+<2934::AID-CNCR9>3.0.CO;2-S","article-title":"Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases","volume":"88","author":"Serafini","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2009.11.011","article-title":"A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: First report of a completed study","volume":"79","author":"Valicenti","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/01621459.1993.10476289","article-title":"On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data","volume":"88","author":"Gaynor","year":"1993","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib14","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib16","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ejca.2011.08.013","article-title":"Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling","volume":"48","author":"Ohri","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.024_bib21","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617341433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617341433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T18:57:19Z","timestamp":1635706639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617341433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0360301617341433"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.024","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First Report of NRG Oncology\/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}